Related Experiment Video
Updated: Jun 3, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Hepatitis a and e infection in international travellers
Joseph Torresi1, Douglas Johnson
1Department of Infectious Diseases, Austin Center for Infection Research, Austin Hospital, Level 7, Harold Stokes Building, 145 Studley Road, Heidelberg, Victoria, 3084, Australia, josepht@unimelb.edu.au.
Abstract:
Hepatitis A is the most common vaccine-preventable infection in travellers. The incidence of hepatitis A for travellers ranges from 3.0 to 11.0 per 100,000 person-months and the case-fatality rate is as high as 2 per 100,000 in non-immune travellers. Hepatitis A vaccine is highly effective in preventing infection, significantly reducing the incidence of hepatitis A in travellers, and an important preventative intervention for the "last-minute" traveller. Hepatitis E virus is an important cause of enterically transmitted hepatitis in developing countries. The overall risk of hepatitis E in travellers visiting endemic countries is relatively low compared to hepatitis A. The majority of cases have been reported from the Indian subcontinent. The case fatality rate for hepatitis E is 1.2%, although this is substantially higher in pregnant women. A vaccine for hepatitis E is not available, and therefore travellers must be made aware of preventative measures to reduce their risk of infection.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Amebiasis
Yellow Fever
Giardiasis
Trichomoniasis
